
Sign up to save your podcasts
Or


On this episode of Stock Movers:
- Meta (META US) shares plunge after the company raised its spending outlook for the year, driven by its AI strategy and higher component pricing. The social media giant projected full-year capital expenditures of $125 billion to $145 billion, exceeding analysts' estimates, and is kicking off a bond sale of between $20 billion and $25 billion in debt.
- Ford (F) shares slide. The automaker raised its full-year profit outlook due to demand for high-margin pickups and SUVs, but warned of pressure from an unexpected rise in commodity costs. The company expects to earn as much as $10.5 billion before interest and taxes this year, and also expects a $2 billion profit hit from rising commodity prices such as steel and aluminum.
- Eli Lilly (LLY) shares gain. The company raised its annual sales and profit forecast due to high demand for obesity medications and its new weight-loss pill. The company now sees 2026 sales rising to as much as $85 billion and 2026 profits in the range of $35.50 a share to $37 a share.
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.6
1919 ratings
On this episode of Stock Movers:
- Meta (META US) shares plunge after the company raised its spending outlook for the year, driven by its AI strategy and higher component pricing. The social media giant projected full-year capital expenditures of $125 billion to $145 billion, exceeding analysts' estimates, and is kicking off a bond sale of between $20 billion and $25 billion in debt.
- Ford (F) shares slide. The automaker raised its full-year profit outlook due to demand for high-margin pickups and SUVs, but warned of pressure from an unexpected rise in commodity costs. The company expects to earn as much as $10.5 billion before interest and taxes this year, and also expects a $2 billion profit hit from rising commodity prices such as steel and aluminum.
- Eli Lilly (LLY) shares gain. The company raised its annual sales and profit forecast due to high demand for obesity medications and its new weight-loss pill. The company now sees 2026 sales rising to as much as $85 billion and 2026 profits in the range of $35.50 a share to $37 a share.
See omnystudio.com/listener for privacy information.

405 Listeners

1,167 Listeners

2,190 Listeners

1,982 Listeners

420 Listeners

1,037 Listeners

1,307 Listeners

62 Listeners

59 Listeners

154 Listeners

83 Listeners

76 Listeners

76 Listeners

8 Listeners

11 Listeners